EDIT

Editas Medicine Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↑ 6/10
  • Value↓ 0/10
Editas Medicine sales and earnings growth
EDIT Growth
Good
  • Revenue Y/Y↓ -8.46%
  • EPS Y/Y↑ 61.51%
  • FCF Y/Y↑ 34.66%
Editas Medicine gross and profit margin trends
EDIT Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -281.60%
  • ROIC 5Y↓ -104.90%
Editas Medicine net debt vs free cash flow
EDIT Risk
Great
  • Debt / Equity↑ 16.3
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -62.4

Editas Medicine stock volatility is higher than the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks